FDA Ad Com set for mortality reduction claim for Glaxo’s Trelegy Ellipta

An FDA advisory committee will meet on Tuesday, April 21, to review and discuss GlaxoSmithKline’s (NYSE:GSK) application seeking a mortality risk reduction claim for COPD inhalation therapy Trelegy Ellipta (fluticasone furoate, umeclidinium, & vilanterol).

The company in-licensed the product from Innoviva (NASDAQ:INVA) (formerly Theravance).

https://seekingalpha.com/news/3543248-fda-ad-com-set-for-mortality-reduction-claim-for-glaxos-trelegy-ellipta